WESTMINSTER, Colo., March 10 /PRNewswire-FirstCall/ -- Allos Therapeutics,
Inc. (Nasdaq: ALTH) announced today the appointment of Paul L. Berns as the
Company's President, Chief Executive Officer and a member of the Board of
Directors, effective immediately. Mr. Berns was most recently President,
Chief Executive Officer and a member of the Board of Directors of Bone Care
International, Inc.
Stephen J. Hoffman, M.D., Ph.D., Chairman of the Board, stated, "Paul has
an outstanding track record of leadership and accomplishment in the
pharmaceutical industry, and we believe he is the ideal candidate to lead the
Company's future growth efforts. On behalf of the Board of Directors, I am
pleased to welcome Paul to the Allos team, and also thank Mike Hart for his
service and dedication to the Company over the past six years."
"I am enthusiastic about joining Allos," said Mr. Berns. "I believe the
Company's product portfolio has significant clinical and commercial potential,
and I look forward to working with my new colleagues in creating value for
patients, employees and shareholders alike."
Mr. Berns brings close to 15 years of pharmaceutical industry experience
to Allos. While leading Bone Care International, Inc. from June 2002 until
its acquisition by Genzyme, Corp. in July 2005, revenues increased nearly
14-fold, the company became profitable and market capitalization increased
from approximately $40 million to a sale value of $719 million. Prior to
joining Bone Care International, Inc., Mr. Berns held senior management
positions at Abbott Laboratories, BASF Pharmaceuticals, and Bristol-Myers
Squibb Company.
With Mr. Berns' appointment, Michael E. Hart resigned his positions as the
Company's President, Chief Executive Officer and Chief Financial Officer, and
David C. Clark, the Company's Corporate Controller and Treasurer, was
appointed to serve as the Company's Principal Financial Officer until a
permanent Chief Financial Officer is appointed.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. The Company's lead product
candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed
to sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation
therapy. EFAPROXYN is currently being evaluated as an adjunct to whole brain
radiation therapy in a pivotal Phase 3 trial in women with brain metastases
originating from breast cancer. The Company's other product candidates are:
PDX (pralatrexate), a small molecule chemotherapeutic agent (DHFR inhibitor)
currently under investigation as both a single agent and in combination
therapy regimens in patients with non-small cell lung cancer and Non-Hodgkin's
lymphoma; and RH1, a small molecule chemotherapeutic agent bioactivated by the
enzyme DT-diaphorase currently under evaluation in patients with advanced
solid tumors. For more information, please visit the Company's web site at:
http://www.allos.com.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, Inc., +1-720-540-5227,
jneiman@allos.com
|
